Your browser doesn't support javascript.
loading
High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination
Farshad Guirakhoo; Shixia Wang; Chang Yi Wang; Hui-Kai Kuo; Wen-Jiun Peng; Hope Liu; Lixia Wang; Marina Johnson; Adam Hunt; Mei Mei Hu; Thomas P. Monath; Alexander Rumyantsev; David Goldblatt.
Afiliación
  • Farshad Guirakhoo; Vaxxinity Inc
  • Shixia Wang; Vaxxinity Inc
  • Chang Yi Wang; United Biomedical Inc Asia
  • Hui-Kai Kuo; United Biomedical Inc Asia
  • Wen-Jiun Peng; United Biomedical Inc Asia
  • Hope Liu; United Biomedical Inc Asia
  • Lixia Wang; Vaxxinity Inc
  • Marina Johnson; Great Ormond Street Institute of Child Health, University College London
  • Adam Hunt; Great Ormond Street Institute of Child Health, University College London
  • Mei Mei Hu; Vaxxinity Inc
  • Thomas P. Monath; Vaxxinity Inc
  • Alexander Rumyantsev; Vaxxinity Inc
  • David Goldblatt; Great Ormond Street Institute of Child Health, University College London
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-484436
ABSTRACT
The highly transmissible Omicron variant has caused high rates of breakthrough infections among vaccinated and convalescent individuals. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increases neutralizing antibody levels by 131-, 61- and 49-fold against ancestral SARS-CoV-2, Omicron BA.1 and BA.2 variants, respectively. Based on the RBD protein binding antibody responses, we estimated a [~]95% efficacy against symptomatic COVID-19 caused by the ancestral strain after a UB-612 booster. Our results support UB-612 vaccine as a potent booster against current and emerging SARS-CoV-2 variants.
Licencia
cc_no
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2022 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2022 Tipo del documento: Preprint
...